Class summary at a glance.

Every drug in the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $736.4Mcombined across class
Total Rx claims: 29.1M7.2M unique beneficiaries
Generic mfrs (active): 43across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Duloxetine

Brand: Cymbalta · 19.8M Part D claims (CY24) · 5.0M beneficiaries · First FDA approval: 2004-08-24

16 generic mfrs 475 plans require PA

Low NADAC$0.085

→

Avg plan cost$0.820

Part D spend $496.0M 10× spread, current vs floor

Class share

67%

of class CY24 spend

View profile →

Venlafaxine

Brand: Effexor · 9.3M Part D claims (CY24) · 2.2M beneficiaries · First FDA approval: 1997-11-01

27 generic mfrs 1 plans require PA

Low NADAC$0.069

→

Avg plan cost$0.889

Part D spend $240.4M 13× spread, current vs floor

Class share

33%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.